Literature DB >> 7407411

Cytotoxicity as an indicator for transport mechanism: evidence that murine bone marrow progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells.

D T Vistica.   

Abstract

Cytotoxicity of melphalan to murine L1210 leukemia cells was reduced to a limiting maximum value of 50% by 2-aminobicyclo[2,2,1]heptane-2-carboxylic acid (BCH), indicating that cytotoxicity is partially dependent on drug uptake by system L. L-Leucine, but not alpha-aminoisobutyric acid (AIB), completely reduced the remaining 50% of drug cytotoxicity. These results contrast with those obtained with a sensitive host tissue, the bone marow progenitor cells of the white cell series (CFU-C), in that a high-affinity leucine transport system corresponding to system L was not identified.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7407411

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Predictive tests in cancer chemotherapy. A reappraisal.

Authors:  R Osieka; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-03-01

2.  Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells.

Authors:  M Dufour; L C Panasci; J St Germain; L Boulet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 3.  Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches.

Authors:  Anastazja Poczta; Aneta Rogalska; Agnieszka Marczak
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

4.  Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.

Authors:  B C Millar; J A Maitland; J L Millar; J B Bell
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

5.  Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.

Authors:  B A Robinson; R D Clutterbuck; J L Millar; T J McElwain
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.